

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**EVEREST MEDICINES**

**云 頂 新 耀**

**Everest Medicines Limited**

**雲頂新耀有限公司**

*(incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1952)**

## **VOLUNTARY ANNOUNCEMENT**

This announcement is made by Everest Medicines Limited (the “**Company**”) on a voluntary basis.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is aware that a generic drug to NEFECON<sup>®</sup> has been approved by the National Medical Products Administration in China. The Board wishes to emphasize that NEFECON<sup>®</sup> is protected by the patent number ZL200980127272.5, and the patent will be valid until 7 May 2029. The Company has registered the relevant patent information in the China’s Patent Information Registration Platform for Marketed Drugs in accordance with the law.

According to Article 11 of China’s Patent Law and the relevant provisions of the “Measures for the Implementation of the Mechanism for Early Settlement of Drug Patent Disputes (Trial Implementation)” (the “**Measures**”), no enterprise or individual may, without the Company’s legal permission, manufacture, use, offer for sale (including market promotion, online listing, etc.), sell, or import products falling within the scope of protection of the aforementioned patents for production and business purposes before the expiration of the patent term; otherwise, it will constitute patent infringement. Based on the Measures, if the relevant generic drug applicant makes a “Type 3 Declaration” (i.e., a commitment not to market the drug before the expiration of the relevant patent right) when submitting the abbreviated new drug application, they should strictly abide by this commitment and fulfill their obligations in good faith. The Company reserves the right to take all subsequent actions in accordance with the law for any suspected infringement that violates the above provisions and commitments.

The Company is committed to bringing breakthrough therapies to China to fill urgent medical needs. A sound patent protection system and an effective Measures are crucial for ensuring the continued accessibility of such major innovative drugs, incentivizing pharmaceutical R&D innovation, and promoting fair and orderly competition in the generic drug industry based on respect for intellectual property rights. It is precisely the system that has ensured the successful development and introduction of breakthrough therapies like NEFECON<sup>®</sup> into China.

Recent years, the intellectual property protection environment in China's pharmaceutical industry has been continuously optimized and improved, providing strong support for pharmaceutical innovation and the healthy development of the industry. In the future, The Company will continue to work with all parties to respect and safeguard intellectual property rights, abide by relevant laws and regulations, and create a fair and equitable competitive environment to promote the sustainable development and accessibility of innovative drugs, ultimately benefiting a wide range of Chinese patients.

By order of the Board  
**Everest Medicines Limited**  
**Yifang Wu**  
*Chairman and Executive Director*

Hong Kong, 30 December 2025

*As at the date of this announcement, the Board comprises Mr. Yifang Wu as Chairman and Executive Director, Mr. Yongqing Luo and Mr. Ian Ying Woo as Executive Directors, Mr. Wei Fu, Mr. William Ki Chul Cho and Mr. Xin Sun as Non-executive Directors, and Ms. Hoi Yam Chui, Mr. Yifan Li and Mr. Shidong Jiang as Independent Non-executive Directors.*